Navigation Links
CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008
Date:10/13/2008

CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValving System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.

IRVINE, Calif. (Business Wire EON) October 13, 2008 -- During the Monday Transcatheter Aortic Valve Replacement sessions at TCT 2008 meeting in Washington, D.C., CoreValve investigators and physician proctors presented clinical data on the subset of patients that are included in the company's post CE-Mark expanded clinical evaluation registry. Patients enrolled in the registry had a predicted 30-day mortality rate of about 23% as measured by the logistical EuroScore. By contrast, the survival rate at one-month post-procedure follow-up for these high-risk and often inoperable octogenarian registry patients was about 90%. Quality of life improvement, as measured by the New York Heart Association (NYHA) functional classification, was significantly improved as well. Follow-up on patients that are now one year post procedure demonstrate good longer term valve function and sustained survival and quality of life benefits. CoreValve believes that complications including neurological events are comparable to traditional aortic valve surgery although there is a modest, but clinically acceptable increase in pacemaker dependency in PAVR patients.

"The growing volume of very positive clinical data from an ever increasing number of physicians is most satisfying," said Eberhard Grube MD, Chief of Cardiology at the HELIOS Heart Center Siegburg, Germany. "In the hands of an experienced user, use of the CoreValve ReValving System is fast becoming a routine alternative for high risk patients suffering from severe aortic stenosis."

"We are highly encouraged by the clinical data from outside the United States that was presented at TCT," added Daniel T. Lemaitre, President and CEO of CoreValve. "Additionally, we continue to see strong sequential growth in procedure volume as 2008 unfolds; a testimony to the significant patient population whom we believe will benefit from our groundbreaking technology."

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at www.corevalve.com.

(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)

Read the full story at http://www.prweb.com/releases/aortic_valve/valve_replacement/prweb1466554.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
2. RF Technologies(R) Announces Code Alert(R) Integrated Care Management Solution
3. CIO Healthcare Summit Announces Dates and VIP Delegates
4. Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region
5. HealthSouth Announces Plans to Build New Hospital in Arizona
6. Life Spine Announces Acquisition of Intellectual Property
7. Robbins & Myers Announces Regular Quarterly Cash Dividend
8. Boston Scientific Announces Third Quarter Adjustments
9. U.S. Department of Labor announces $1.2 million grant to provide nearly 700 North Carolina workers with health insurance payments as part of Trade Adjustment Assistance benefits
10. Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant
11. Disaboom Announces Preliminary Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) :  Highly encouraging registry data also presented at TCT 2008 
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising ... 550 employees of Sun Health Senior Living (SHSL) may not share those ... doctor and prescription copays for the year, while holding the line on increasing their ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute ... a six-week smoking cessation class starting June 6 at their clinic in downtown Tampa. ... . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... Top Doc! Along with his wonderful accolades and stellar patient reviews, Dr. Batelli ... Dr. Batelli! , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that doesn't ... Bar, has ignited an undeniable buzz in the protein product community by offering ... any doughnut.  These doughnuts are packed with 11 grams of protein and made from ...
(Date:5/26/2016)... York, NY (PRWEB) , ... May 26, 2016 , ... ... have lips been so central to popular cosmetic improvement efforts. Record numbers of clients ... kissers appear more prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
Breaking Medicine Technology: